DELTA 3 trial investigated delgocitinib cream for the treatment of adults with moderate-to-severe chronic hand eczema (CHE), a condition with a considerable unmet need. The first of two LEO Pharma late-breaker presentations at AAD is part of a wide-ranging data program with eight abstracts accepted in total for the meeting. In the periods when the disease is controlled within the 36 weeks, no treatment was administered.